Radiation Oncology, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, USA.
Epidemiology and Biostatistics, MSKCC, New York, NY, USA.
Leuk Lymphoma. 2023 Dec;64(13):2195-2201. doi: 10.1080/10428194.2023.2255706. Epub 2023 Sep 14.
Extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue (BALT) is a rare cancer for which optimal treatment strategies are undefined. Retrospective analyses suggest excellent outcomes with surgical resection for localized BALT lymphoma; however, the role of radiotherapy remains underexplored. We report the largest-to-date single-center analysis of 13 primary BALT lymphoma patients treated with radiotherapy. Of 15 treated lesions, we report a 100% response rate with complete response (CR) achieved in 67% of lesions. Among 10 lesions treated with very low-dose radiotherapy (VLDRT; 4 Gray [Gy]), 6 (60%) achieved a CR; among 5 lesions treated with full-dose radiotherapy (24-36 Gy), 4 (80%) achieved a CR. There were no local recurrences. Only one patient, treated with 30 Gy, developed an acute grade 3/4 toxic effect. There were no events of radiation-induced secondary malignancies. Our institutional experience indicates that radiotherapy, including VLDRT, is a safe and effective treatment for primary BALT lymphoma.
支气管相关淋巴组织(BALT)结外边缘区淋巴瘤是一种罕见的癌症,目前尚无明确的最佳治疗策略。回顾性分析表明,对于局限性 BALT 淋巴瘤,手术切除的疗效极佳;然而,放疗的作用仍未得到充分探索。我们报告了迄今为止最大的单中心分析,共纳入 13 例接受放疗的原发性 BALT 淋巴瘤患者。在 15 个治疗的病灶中,我们报告了 100%的应答率,其中 67%的病灶达到完全缓解(CR)。在接受极低剂量放疗(VLDRT;4 戈瑞[Gy])的 10 个病灶中,有 6 个(60%)达到 CR;在接受全剂量放疗(24-36 Gy)的 5 个病灶中,有 4 个(80%)达到 CR。无局部复发。仅有 1 例接受 30 Gy 放疗的患者发生急性 3/4 级毒性反应。无放射性继发性恶性肿瘤事件。我们的机构经验表明,放疗(包括 VLDRT)是治疗原发性 BALT 淋巴瘤的一种安全有效的治疗方法。